High Revenue Growth Stocks in Health Care
Companies with year-over-year revenue growth exceeding 10%, indicating meaningful business expansion.
The information on this page is for informational purposes only and does not constitute investment advice, financial advice, or any recommendation. Billiver does not recommend buying, selling, or holding any security. Past performance is not indicative of future results.
Data may be delayed and accuracy is not guaranteed. All investment decisions are solely your responsibility. Verify information independently and consult a qualified financial advisor before investing. About · Methodology
77 Companies Meeting Criteria
Showing 51–77 of 77 companies, ranked by Revenue Growth.
| # | Company | Revenue Growth | Revenue |
|---|---|---|---|
| 51 | LFSTLifeStance Health Group, Inc. | 13.9% | $1.3B |
| 52 | CONConcentra Group Holdings Parent, Inc. | 13.9% | $1.9B |
| 53 | FLGTFulgent Genetics, Inc. | 13.8% | $283M |
| 54 | CDNACareDx, Inc. | 13.8% | $334M |
| 55 | INSPInspire Medical Systems, Inc. | 13.6% | $803M |
| 56 | AORTArtivion | 13.6% | $423M |
| 57 | LMATLeMaitre Vascular | 13.5% | $220M |
| 58 | STESteris | 13.3% | $5.5B |
| 59 | WRBYWarby Parker Inc. | 13.0% | $851M |
| 60 | OPCHOption Care Health | 13.0% | $5.0B |
| 61 | ELVElevance Health | 12.5% | $194.8B |
| 62 | TCMDTACTILE SYSTEMS TECHNOLOGY INC | 12.5% | $293M |
| 63 | MCKMcKesson Corporation | 12.4% | $359.1B |
| 64 | UNHUnitedHealth Group | 11.8% | $435.2B |
| 65 | DGXQuest Diagnostics | 11.8% | $10.8B |
| 66 | INNVInnovAge Holding Corp. | 11.8% | $854M |
| 67 | MMSIMerit Medical Systems, Inc. | 11.8% | $1.4B |
| 68 | MOHMolina Healthcare | 11.7% | $44.5B |
| 69 | EWEdwards Lifesciences | 11.5% | $5.4B |
| 70 | RDNTRadNet, Inc. | 11.5% | $1.8B |
| 71 | MDLNMedline Inc. | 11.5% | - |
| 72 | CICigna | 11.2% | $268.1B |
| 73 | LIVNLivaNova | 10.7% | $1.3B |
| 74 | EHCEncompass Health | 10.5% | - |
| 75 | IDXXIdexx Laboratories | 10.4% | $4.2B |
| 76 | PGNYProgyny | 10.4% | $1.2B |
| 77 | HUMHumana | 10.1% | $126.4B |
Understanding Revenue Growth
Revenue growth above 10% is considered strong for large-cap companies. It typically signals increasing demand, successful new products, or geographic expansion. Growth rates are calculated from the two most recent annual SEC filings. One-time events like acquisitions can inflate growth temporarily.
YoY Revenue Growth > 10%
Results are based on SEC EDGAR filings. Companies with missing, unreliable, or extreme outlier values are excluded from screening.
Related Rankings
See the top companies ranked by these related metrics